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ABSTRACT
Pre-eclampsia is a pregnancy-related condition characterized by hypertension, proteinuria and
endothelial dysfunction. VEGF165b, formed by alternative splicing of VEGF (vascular endothelial
growth factor) pre-mRNA, inhibits VEGF165-mediated vasodilation and angiogenesis, but has not
been quantiﬁed in pregnancy. ELISAs were used to measure means+ −S.E.M. plasma VEGF165b, sEng
(soluble endoglin) and sFlt-1 (soluble fms-like tyrosine kinase-1). At 12 weeks of gestation, the
plasma VEGF165b concentration was signiﬁcantly up-regulated in plasma from women who main-
tained normal blood pressure throughout their pregnancy (normotensive group, 4.90+ −1.6 ng/ml;
P<0.01, as determined using a Mann-Whitney U test) compared with non-pregnant women
(0.40+ −0.22 ng/ml). In contrast, in patients who later developed pre-eclampsia, VEGF165bl e v e l s
were lower than in the normotensive group (0.467+ −0.209 ng/ml), but were no greater than non-
pregnant women. At term, plasma VEGF165b concentrations were greater than normal in both pre-
eclamptic (3.75+ −2.24 ng/ml) and normotensive (10.58 ng/ml+ −3.74 ng/ml; P>0.1 compared with
pre-eclampsia) pregnancies. Patients with a lower than median plasma VEGF165b at 12 weeks had
elevated sFlt-1 and sEng pre-delivery. Concentrations of sFlt-1 (1.20+ −0.07 and 1.27+ −0.18 ng/ml)
andsEng(4.4+ −0.18and4.1+ −0.5 ng/ml)weresimilarat12 weeksofgestationinthenormotensive
and pre-eclamptic groups respectively. Plasma VEGF165b levels were elevated in pregnancy, but
this increase is delayed in women that subsequently develop pre-eclampsia. In conclusion, low
VEGF165b may therefore be a clinically useful ﬁrst trimester plasma marker for increased risk of
pre-eclampsia.
INTRODUCTION
Pre-eclampsia, the pregnancy-related disease of hyper-
tension, proteinuria and oedema, is responsible for
approx. 12% of the world’s annual 514000 maternal
deaths [1]. Aside from maternal and fetal death, the
condition may also result in intra-uterine growth
restriction, seizures (eclampsia), renal or liver failure,
and placental abruption. Despite much investigation,
the pathological processes underlying this disease are
still largely undiscovered. Previous investigations have
focussed on defective placental implantation as an
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important aetiological factor, with the resulting release
of placentally derived circulating factors, which cause
endothelial dysfunction [2–4]. At the microvascular
level, there is a state of vasoconstriction from smooth
muscle contraction, increased vascular permeability and
anti-angiogenesis [5], which correspond to the clinical
ﬁndings of high BP (blood pressure), oedema and a
characteristically small placenta at delivery of the baby.
The VEGF (vascular endothelial growth factor)
family is thought to be one of the important molecular
systems involved in the pathogenesis of pre-eclampsia.
Conventional VEGF, also known as VEGF-A, is made
up of six different isoforms formed from alternative
exon splicing, resulting in proteins of varying amino acid
length, termed VEGFxxx.V E G F 165 is the most common
isoform of VEGFxxx, and consists of 165 amino acids.
VEGF165 acts via its receptor VEGFR-2 to increase
vascular permeability, vasodilation and angiogenesis [6].
Endogenous alternative splicing of the VEGFR results in
soluble VEGFR-1 {also known as sFlt-1 [soluble Flt-1
(fms-like tyrosine kinase-1)]}, which binds to VEGF
and inhibits its function [6]. High levels of sFlt-1 have
been documented in pre-eclampsia [7].
VEGFlevelsinpre-eclampsiahavebeenmeasuredbya
number of techniques, with conﬂicting results according
to the technique used. When measured by commercial
sandwich ELISAs,which have been proposed to measure
only the free unbound forms of VEGF, levels appear to
be reduced in pre-eclampsia [8,9]. When measured by
RIA or cEIA [competitive EIA (enzyme immunoassay)],
VEGF levels have been shown to increase substantially
[10]. This discrepancy has been proposed to be due to
theselattertwomethodsnotbeingaffectedbycirculating
binding proteins [10,11].
In 2002, an alternative family of VEGF-A isoforms
were identiﬁed, termed VEGFxxxb. These are the same
size as conventional VEGF-A, but are alternatively
spliced in exon 8 [12]. This alternative splice site selection
results in an alternate six amino-acid C-terminus, which
affects the property of the isoforms. VEGF165bi st h e
most widely studied of these isoforms. VEGF165bh a s
been shown to inhibit the effects of VEGF165 by binding
to its principal receptor VEGFR-2 and preventing it
fromexertingitsphysiologicaleffects,suchasendothelial
cell proliferation and migration. VEGF165b also binds to
and activates Flt-1 (VEGFR-1), resulting in a transient
increase in capillary hydraulic conductivity, but no sus-
tained increase in permeability, in contrast with VEGF165
[13]. A previous study [14] of VEGF165b in term placenta
detected a decrease in VEGFxxxb expression in pre-ecla-
mptic placenta compared with control placenta, and an
uncoupling of the splicing link between VEGF165ba n d
VEGF165. To determine whether VEGF165b may play a
role in the pathogenesis of pre-eclampsia, we have in-
vestigatedtheexpressionofVEGF165binmaternalplasma
from normotensive and pre-eclamptic pregnancies.
MATERIALS AND METHODS
Subjects
Pregnant subjects were recruited from St Michael’s
Maternity Hospital, Bristol, U.K. between June 2006 and
December2007.Atotalof18non-pregnantfemales,aged
between 20 and 39 years, were recruited from the Uni-
versity of Bristol, Bristol, U.K. The protocol for the
present study was granted ethical approval by Central
and South Bristol Research Ethics Committee, and all
subjects provided written informed consent. A total
of 50 subjects were recruited from routine antenatal
clinics in the ﬁrst trimester of pregnancy. Subjects were
aged between 17 and 42 years. Blood was taken from
subjects for VEGF165b quantiﬁcation at recruitment,
and at a further three times at 28, 34 and 37 weeks of
gestation. Pre-eclampsia was deﬁned as a BP 140/
90 mmHg on two or more occasions measured 6 h apart
and 300 mg of proteinuria/24 h, in the absence of a
urinary tract infection, occurring after 20 weeks of gest-
ation. Five patients who later developed pre-eclampsia
had further blood taken at disease diagnosis. Following
venepuncture, blood was immediately centrifuged at
179 gfor10 minat5◦C,thesupernatantwasremovedand
stored at −80◦C until protein quantiﬁcation. Subjects
also received fetal growth ultrasound scans at 28, 34 and
37 weeks of gestation to screen for intra-uterine growth
restriction secondary to pre-eclampsia. During the study
period,afurther20patientswhodevelopedpre-eclampsia
in the third trimester were recruited into the study at
disease diagnosis, and received fetal growth scans at the
point of recruitment into the study. In these cases, plasma
from their ﬁrst trimesters was obtained from aliquots
of frozen plasma stored under the same standard blood
storage conditions by the hospital’s virology department.
Sample size was calculated to observe an 80% change
in mean VEGF165b levels at P<0.05 with a power of
>90% given an S.D. equivalent to the mean (calculated
using G Power).
VEGF165bE L I S A
The anti-VEGFxxxb antibody (MAB3045, clone 56/1;
R&D Systems) was coated overnight on to the surface of
a sterile Immulon-2HB 96-well plate at a concentration
of 200 μg/ml. This antibody recognizes an epitope
within a nine amino-acid sequence at the C-terminus
of human VEGF165b. The plate was washed three times
with 100 μl/well of PBS/0.05% Tween 20. The plate was
blocked for 12 h with Superblock (250 μl/well; Pierce).
Serial dilutions of recombinant VEGF165b standards
(R&D Systems) diluted in PBS/1% (w/v) BSA up to a
concentrationof16 ng/mlwerethenaddedtothewellsin
triplicate (200 μl/well). Plasma samples were also added
in triplicate (200 μl/well). Plates were then incubated at
room temperature (22–24◦C) with shaking for 2 h, and
were then washed as above. Biotinylated anti-(human
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VEGF) afﬁnity-puriﬁed polyclonal antibody (50 ng/ml;
BAF293; R&D systems), as a detection reagent, was
added (200 μl/well) and incubated at room temperature
with shaking for 2 h with the plate protected from light.
Following a further wash, 100 μl of HRP (horseradish
peroxidase)-streptavidin diluted 1:200 in PBS was added
for 20 min protected from light, and then substrates A
and B (100 μl/well) were added following washing. After
25 min, the colour change was stopped on addition of
1 mol/l H2SO4 (50 μl/well), and the plates were read
immediately at a wavelength of 450 nm using a plate
photospectrometer (Dynex Technologies). Revelation
Quicklink 4.25 software was used to construct a standard
curve from mean absorbance values of VEGF165bs t a n -
dards, which enabled estimation of the VEGF165b con-
centration in plasma samples. VEGF165b sample concen-
trations were quantiﬁed at multiple different concentra-
tions in triplicate to ensure values were in the range of
the ELISA. Values are expressed as means+ −S.E.M.
This sandwich ELISA measures total circulating
VEGF165b. It has been shown not to detect VEGF165,
and sFlt-1 is known not to interfere due to the use of
antibodies against the VEGF165b molecule with epitopes
at different parts of the molecule [15]. The CVs
(coefﬁcients of variation) of this assay in quantifying
VEGFxxxbwas17%forwithin-subjectvariation(samples
taken at least a week apart), and 7% for within-sample
variation, whereas the between-sample CV was >200%,
indicating consistency of assay and a signiﬁcant variation
among the population. VEGF165b concentration in
maternal plasma was quantiﬁed at 8–12, 28, 34 and
37 weeks of gestation in 45 normotensive subjects and
four subjects recruited in the ﬁrst trimester who later
developed pre-eclampsia in the third trimester. The
VEGF165b concentration was also quantiﬁed in 21 pre-
eclamptic patients at 12 weeks of gestation and again in
the third trimester at disease diagnosis. A similar version
of this ELISA is now available as a DuoSet Kit from
R&D Systems.
Endoglin and sFlt-1 ELISAs
ELISAs for sEng (soluble endoglin) and sFlt-1 were
carriedoutonmaternalplasmasamplesusingcommercial
ELISA kits from R&D Systems (DNDG00 and
DVR100B respectively), according to the manufacturer’s
instructions. Values are expressed as means+ −S.E.M.
Total VEGF ELISA and EIA
Total circulating VEGF was quantiﬁed by commercial
ELISA (45-VEGFH-0111; Alpco Diagnostics) and by
cEIA (QIA69; Calbiochem). The EIA measures both
bound and free forms of VEGF. cEIAs for total VEGF
quantiﬁcation have not been commercially available
since 2006 and we had access to only a single 96-well
EIA. For this reason, total VEGF quantiﬁcation was
possible in only ten patients. For each plasma sample, the
Table 1 Clinical characteristics of the study participants
Values are means+ −S.E.M. NA, not applicable.
Normotensive Pre-eclamptic
Characteristic subjects (n=45) patients (n=25)
Maternal age (years) 30+ −0.8 30+ −1.3
Gestational age at diagnosis NA 34+5+ −0.6
(weeks)
Gestational age at birth (weeks) 39+3+ −0.17 36+3+ −0.47
Systolic BP (mmHg) <140 151+ −3.1
Diastolic BP (mmHg) <90 98+ −1.7
Proteinuria (g/24 h) <0.3 1.3+ −0.17
Primiparous (%) 58 52
Birthweight (g) 3495+ −481 2513+ −166
Platelet count (109/l) 259+ −10 206+ −17
Creatinine (mmol/l) 60+ −1.3 79+ −2.5
VEGF concentration was determined both by ELISA
and EIA. Values are expressed as means+ −S.E.M.
RESULTS
During the study period, 100 patients were recruited: 25
patients had pre-eclampsia and 45 remained normotens-
ive. Of the 30 recruits who were excluded from the
study, ﬁve developed pregnancy-induced hypertension,
one developed idiopathic fetal growth restriction, nine
chose not to attend follow-up appointments due to
social reasons, two experienced intra-uterine deaths
at 21 and 28 weeks of gestation, three experienced
pre-term labour in the absence of pre-eclampsia, and ten
with pre-eclampsia had no ﬁrst trimester blood sample
available.
The mean maternal age within the normotensive
(n=45) and pre-eclamptic (n=25) groups was 30+ −0.8
and 30+ −1.3 years respectively (Table 1). There were
no differences in smoking status or ethnicity between
the groups. Within the pre-eclamptic group, the mean
gestational age at diagnosis was 34+5+ −0.6 weeks, the
mean proteinuria was 1.3+ −0.17 g/24 h and the mean BP
was 151/98+ −3.1/1.7 mmHg (Table 1). Mean birthweight
within the pre-eclamptic and normotensive groups was
2513+ −166 and 3495+ −481 g respectively. Of the 25
pre-eclamptic patients, six developed early-onset pre-
eclampsia (<34 weeks of gestation) and 12 developed
pre-eclampsia between 34 and 37 weeks of gestation. The
remaining seven patients developed pre-eclampsia at full
term. Five of the 25 pre-eclamptic patients developed
severe pre-eclampsia [according to the Royal College of
Obstetricians and Gynaecologists criteria: systolic BP
>169 mmHg or diastolic BP >109 mmHg with protein-
uria>1 g/24 h;ortheoccurrenceofHELLP(haemolysis,
elevated liver enzymes and low platelet) syndrome]. Five
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Figure 1 Measurement of VEGF165b levels in human plasma
(Upper panel) At 12 weeks of gestation, VEGF165bw a si n c r e a s e di np l a s m a
from pregnant women who went on to have normotensive pregnancies (n=45)
compared with non-pregnant women. This was not the case in patients who
subsequently developed severe early-onset and non-severe pre-eclampsia (n=25;
P =0.0003, as determined using a one-way ANOVA and Kruskal–Wallis test).
Subgroup analysis of severe/early-onset pre-eclampsia patients (n=9) compared
with normotensive subjects also showed that VEGF165b was signiﬁcantly lowered
(P =0.008, as determined using a Mann–Whitney U test). (Lower panel)
VEGF165b levels in both pre-eclamptic patients and normotensive subjects
were increased in the third trimester (P =0.0012, as determined using a
Mann–Whitney U test). Values are means+ −S.E.M. PET, pre-eclampsia.
of the 25 fetuses born to pre-eclamptic mothers had
growth restriction (ultrasonically deﬁned as estimated
fetal weight <10th percentile for gestational age
with further evidence of placental insufﬁciency, such as
oligohydramniosorabnormalumbilicalarteryDopplers)
[16].
Increased VEGF165b in pregnancy
Plasma VEGF165b concentrations from non-pregnant
women were 0.40+ −0.22 ng/ml. In the normotensive
group, circulating plasma VEGF165b at 12 weeks of
gestation was signiﬁcantly increased (4.90+ −1.66 ng/ml;
P<0.001, as determined using a Mann–Whitney U test;
Figure 1, upper panel) and remained so throughout
pregnancy.
Reduced ﬁrst trimester VEGF165bi n
patients who later develop pre-eclampsia
At 12 weeks of gestation, the plasma VEGF165b
concentration was signiﬁcantly lower in patients who
later developed pre-eclampsia (0.467+ −0.209 ng/ml)
compared with plasma from normotensive pregnancies
(Figure 1, upper panel). When the severe early-onset pre-
eclampsia subgroup was analysed, a low ﬁrst trimester
VEGF165b concentration was also predictive at 12 weeks
(P=0.008,asdeterminedusingaMann–WhitneyU test).
In contrast, at term there was no signiﬁcant difference in
plasma VEGF165b concentrations between pre-eclamptic
(3.75+ −2.24 ng/ml) and normal (10.58+ −3.74 ng/ml)
pregnancies (Figure 1, lower panel). Thus pre-eclampsia
was associated with an 8+ −1.8-fold increase in plasma
VEGF165b from the ﬁrst trimester to pre-delivery
compared with a 2+ −0.3-fold increase in normotensive
plasma (P<0.0012, as determined using a Mann–
Whitney U test).
Patients with a lower than median plasma VEGF165b
at 12 weeks had elevated sFlt-1 and sEng just before
delivery. Concentrations of sFlt-1 and sEng were similar
at 12 weeks of gestation in the normotensive and pre-
eclampticgroups(Figure2,left-handpanel).Therefore,at
12 weeksofgestation,neithersFlt-1norsEngwereableto
predict the onset of pre-eclampsia later in the pregnancy
(see Figure 6 middle and right-hand panels). At disease
diagnosis, however, both sFlt-1 (Figure 2, middle panel)
and sEng (Figure 2, right-hand panel) were signiﬁcantly
up-regulated compared with normotensive subjects
(P<0.001,asdeterminedusingaMann–WhitneyU test).
VEGF165b predicts sFlt-1 and sEng
The reduced ﬁrst trimester levels of VEGF165bw e r ea b l e
to predict the elevated sFlt-1 which occurred with the
onset of pre-eclampsia (Figure 3, upper panel; P=0.028,
as determined using a Mann–Whitney U test); however,
VEGF165b concentrations in the ﬁrst trimester did
not correlate with the elevated sEng of pre-eclampsia
(Figure 3, lower panel).
Commercial total VEGF ELISAs
underestimate total VEGF levels
Total circulating VEGF was quantiﬁed in the same
plasma samples both by commercial ELISA and EIA.
When quantiﬁed by ELISA, VEGF concentrations
were on average 2500-fold lower than when quantiﬁed
by EIA (Figure 4; P<0.0001, as determined using a
Mann–Whitney U test).
VEGF165b accounts for the majority of
total circulating VEGF in the third
trimester in pre-eclamptic pregnancy
In ﬁve patients from each group, we were able to
quantify VEGF165b and total VEGF in the same samples.
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Figure 2 First trimester sFlt-1 and sEng do not predict an increased risk of pre-eclampsia
(Left-hand panel) At 12 weeks of gestation, healthy subjects and subjects who later developed pre-eclampsia had similar levels of both sFlt-1 and sEng. Neither plasma
marker was able to predict pre-eclampsia at 12 weeks of gestation. Pre-eclampsia was associated with an up-regulation of maternal plasma levels of sFlt-1 (middle
panel) and sEng (right-hand panel) relative to ﬁrst trimester levels. In normotensive pregnancies, plasma levels of both molecules increased with advancing gestational
age by 2.8-fold (sEng) and 5.3-fold (sFlt-1). P <0.001, as determined using a Mann–Whitney U test. Values are means+ −S.E.M. PET, pre-eclampsia.
Figure 3 Lack of up-regulation of VEGF165b in the ﬁrst
trimester is able to predict the elevated sFlt-1 concentration
occurring with the onset of pre-eclampsia but not sEng
For sFLt-1, P =0.028, as determined using a Mann–Whitney U test. However, ﬁrst
trimester VEGF165b does not correlate with sEng concentration at pre-eclampsia
diagnosis.
VEGF165b expression increased in both pre-eclampsia
and normotensive pregnancy with increasing gestational
age. At 12 weeks of gestation, VEGF165b accounted for
10.5+ −20% of total plasma VEGF in patients that went
Figure 4 Total VEGF was quantiﬁed both by EIA and ELISA
in maternal plasma from normotensive and pre-eclamptic
pregnancies (n=10)
Detectable levels of VEGF were 2500-fold lower when measured by ELISA compared
with EIA (P <0.0001 as determined using a Mann–Whitney U test). PET,
pre-eclampsia. Values are means+ −S.E.M.
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Figure 5 Increase in VEGF levels observed during pregnancy
are primarily due to increased VEGF165b
At 12 weeks, only a small proportion of total VEGF (10–18%) was VEGF165b
(n=10). In contrast, at term approx. 50% of the VEGF was VEGF165bi n
normotensive subjects, whereas in pre-eclampsia 70% of total VEGF was VEGF165b.
Values are means+ −S.E.M. PET, pre-eclampsia.
on to develop pre-eclampsia compared with 18.1+ −10%
in control subjects (Figure 5). With the onset of pre-
eclampsia, VEGF165b accounted for the majority of
total circulating VEGF, comprising 69.3+ −21% of total
plasma VEGF in the patient group and 49+ −12% in the
control group.
VEGF165b levels at 12 weeks predict
pre-eclampsia
To determine which of VEGF165b, sFlt1 and sEng
are more accurate prognostic factors, ROC (receiver
operating characteristic) curves were generated by
calculating sensitivity (proportion of times that the
test predicts pre-eclampsia) and speciﬁcity (proportion
of times that the test excluded pre-eclampsia). Thus a
high sensitivity value would include all patients, but
if not discriminatory would provide a low speciﬁcity
value (and would include false positives). Thus a non-
discriminatory test would give a straight line with a slope
of 1 and an AUC (area under the curve) of 0.5. A perfect
discriminatorytestwouldhaveanAUCof1.0.Asshown
in Figure 6 (left-hand panel), VEGF165b levels have an
AUCsigniﬁcantlygreaterthan0.5incontrastwithsFlt-1
(Figure 6, middle panel) and sEng (Figure 6, right-hand
panel).
DISCUSSION
There have been a number of studies investigating the
VEGF family of proteins in pre-eclampsia [4,17,18],
which have suggested that they may play a role in its
pathophysiology [19,20]. In the present study, the total
VEGF levels measured by EIA are consistent with those
measured previously using this assay methodology [11]
and by those using an independent method, the RIA [10].
In contrast, the ELISA results in the present study from
the same samples gave much lower readings, consistent
withpreviousELISAreportsofplasmaVEGF[21].These
experiments therefore highlight the discrepancy reported
previously between measurements of total circulating
VEGF in plasma by commercial ELISAs compared with
cEIA or RIA [22]. The antibodies used in the ELISA
are two monoclonals raised against the VEGF peptide
sequence and thus may be raised against a similar or
identical epitope. The ELISA appears to yield artiﬁcially
low results, presumably as VEGF is bound by agents in
plasma which prevent its detection by both antibodies
simultaneously. sFlt-1 does not affect this ELISA when
given as a recombinant protein [15], but the effect of en-
doglin or other plasma constituents have not been tested.
The discrepancy was particularly striking after measure-
ment of VEGF165b levels, using an ELISA that detects
plasmaVEGF165busingtwoantibodiesthathaveepitopes
on completely separate parts of the antigen (VEGF)
molecule. It is therefore rather disturbing that the cEIA
is no longer commercially available and was withdrawn
from sale by all known suppliers between 2006 and 2007.
Of the VEGF family, VEGF165, the most widely stud-
iedform[6],isknowntoincreasevascularleakage,induce
vasodilation and promote angiogenesis. Although this
isoform is up-regulated in pre-eclampsia, its metabolic
activitiesmaybeblockedbyotherproteinswhichbindto
VEGF andinhibititsfunction.sFlt-1andsEngbothbind
to VEGF and prevent it from exerting its physiological
effects [23]. sFlt-1 is an anti-angiogenic molecule that
is able to induce a pre-eclamptic-like syndrome of
hypertension and proteinuria when administered to
pregnant rats [7]. sEng is an anti-angiogenic protein that
inhibits TGF (transforming growth factor) β1 and β3
signalling and increases the severity of pre-eclampsia
occurring in pregnant rats treated with sFlt-1 [24].
However, neither molecule can be used clinically as a
ﬁrst trimester marker of pre-eclampsia as sFlt-1 levels
are observed to increase only 5 weeks before the onset of
the clinical disease [25], and sEng concentrations become
elevated at 17 weeks of gestation [23].
In 2002, VEGF165b was identiﬁed in normal renal
cortex and was subsequently shown to be present in
many different tissues, and forms the majority of VEGF
in tissues such as human colon [15] and vitreous [26].
VEGF165b is relatively down-regulated in many condi-
tions, including prostate, renal, bowel and skin cancers
[12,15,25,27,28], diabetic retinopathy [26], Denys–Drash
Syndrome [29] and in the placenta of patients with
pre-eclampsia [14]. The mechanisms underlying these
changes in expression are still under investigation, but
the reduction is associated with excess angiogenesis.
VEGF165b has been shown to be anti-angiogenic in
animal models of VEGF165-induced blood vessel growth
in the cornea [30], mouse subcutaneous tissue [31] and
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Figure 6 ROC curves for ﬁrst trimester VEGF165b, sFlt-1 and sEng in the prediction of pre-eclampsia
AUC was highest for VEGF165b[ P =0.0047 compared with random (0.5)]. AUC for sEng and sFlt-1 were 0.59 (P =0.34) and 0.56 (P =0.43) respectively, and
were not different from random (0.5).
rat mesentery [27], and inhibits physiological [32] and
pathological [15,30,32] angiogenesis. Studies have also
shown that VEGF165b transiently, but not chronically,
increases hydraulic conductivity [13].
The results shown in the present study indicate that
VEGF165b fails to be up-regulated in the ﬁrst trimester
in those pregnancies that will later be complicated by
pre-eclampsia. It can be concluded that VEGF165bm a y
be a clinically useful ﬁrst trimester marker for increased
pre-eclampsia risk, providing for instance a guide to
commencement of ﬁrst trimester oral aspirin therapy, as
thisdecreasestheincidenceofpre-eclampsiaby15%[33].
It is not clear what mediates the up-regulation of
VEGF165b in early pregnancy or what prevents it in
women who will develop pre-eclampsia, and further
work must be done to investigate this ﬁnding. The failure
of up-regulation may be reﬂective of the aetiology or
could be contributory to the subsequent pre-eclampsia.
For instance, in the ﬁrst trimester, the reduced anti-
angiogenic VEGF165b compared with normal pregnancy
may reﬂect a maternal vasculature response to try and
correct the defective implantation processes underlying
the disease, or the failure to up-regulate VEGF165bm a y
contribute to defective implantation.
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